FOR-FD-24-014: FDA Announces New Grants for Enhancing Drug Development and Regulatory Science

The U.S. Food and Drug Administration (FDA) has introduced a new funding opportunity, FOR-FD-24-014, focused on Collaborations to Enhance Drug Development and Regulatory Science. This initiative is part of the FDA’s commitment to accelerating drug product innovation and enhancing the safety, efficacy, quality, and performance of drug products. With an award ceiling of $5,000,000, the funding is intended to support cooperative agreements that manage and facilitate Public-Private Partnerships and Collaborative activities under the Critical Path Initiative.

This program invites a broad range of eligible applicants, including Native American tribal governments, various nonprofit organizations, special district governments, small businesses, and educational institutions, among others. The main goal is to develop innovative, collaborative projects in research, education, and outreach that align with the FDA’s drug development priorities. The projects encouraged under this notice of funding opportunity are those that support efforts to accelerate drug product development, advance manufacturing approaches, translate basic science discoveries into therapeutics, and enhance drug product safety and effectiveness. These initiatives are crucial for fostering innovation in drug development and regulatory science, directly impacting public health and consumer protection. The FDA and grantees will work closely to identify and implement projects that meet these objectives, contingent upon the availability of funding and alignment with the FDA’s strategic goals.